Analysis Data Reviewer's Guide (OBX319-301)
📚 Part of the OBX-319 Regulatory Dossier — Reader's Guide. This article shows the live document; edits to the source appear here automatically.
This is a mock / simulation document, made for a portfolio and for learning. The drug (GLPI-103), the sponsor, the people, and the data are all fictional. It is not a real regulatory submission and has no clinical, legal, or regulatory standing. What is real is the shape of the thing — the document structure, the standards it follows, and the analysis methods; the content inside is illustrative.
What it is. Analysis Data Reviewer's Guide (OBX319-301)
Why it exists. Clinical study documentation supporting the efficacy and safety of the program.
How it is produced here. The numbers come straight from the study's simulated Phase 3 dataset — they are calculated from the data, not typed in by hand. That is why you see the same figures repeated across the protocol, the analysis plan, the report, and the summaries: they all read from the same source.
Format & governing standard. —
Analysis Data Reviewer's Guide (OBX319-301)
Document ID: DEF-301-ADRG
Version: 1.0
Change History: 1.0 — Initial issue.
Standard(s): CDISC ADaM
Analysis Data Reviewer's Guide (ADRG) — OBX319-301
Orients the reviewer to the ADaM datasets for OBX319-301: analysis-set derivations (ADSL flags), the BDS structures (ADLB/ADVS/ADAE) and the time-to-event dataset (ADTTE), traceability from SDTM to ADaM to the TFL outputs, and any analysis conventions. Conformance is summarised in the CDISC validation report. CDISC ADaM; Define-XML 2.1.
Comments (0)
No comments yet. Be the first to say something!